Table 1.

Summary of the clinical and molecular characteristics for the study cohort

Sex (N = 40)
 Males26 (65%)
 Females14 (35%)
Age (N = 39), y
 Median64
 Range45–87
Site of primary (N = 35)
 Colon28 (80%)
 Rectum7 (20%)
Diagnosis (N = 35)
 Synchronous21 (60%)
 Metachronous14 (40%)
Previous chemotherapy (N = 33)
 Yes13 (39%)
 No20 (61%)
Neoadjuvant (N = 31)
 Yes17 (55%)
 No14 (45%)
KRAS status (N = 40)
 Codon 1222 (55%)
 Codon 135 (12.5%)
 Codon 611 (2.5%)
 Codon 1464 (10%)
BRAF status (N = 40)
 Codon 6003 (7.5%)
NRAS status (N = 40)
 Codon 121 (2.5%)
 Codon 613 (7.5%)
PIK3CA status (N = 39)
 Codon 5454 (10%)
 Codon 5461 (2.6%)
 Codon 10473 (7.5%)